CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 49 enrolled
Drug / intervention
Simvastatin +1 moredrug
Likely dose
Simvastatin 40mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01142336
NCT01142336Phase 4Completed
CompareCT.gov

Effects of Simvastatin on CSF AD Biomarkers in Cognitively Normal Subjects

University of Washington·interventional·Posted Jun 11, 2010·Updated Jul 28, 2017

In Brief

A Phase 4 clinical trial evaluating Simvastatin and Placebo for Alzheimer's Disease. Completed, enrolled 49 participants across 1 site.

Detailed Summary

A year-long randomized, double-blind, placebo-controlled trial of simvastatin to see if it produces beneficial changes in cerebral spinal fluid proteins associated with Alzheimer's disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesUnited States
CollaboratorsSeattle Institute for Biomedical and Clinical Research, VA Puget Sound Health Care System

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 11, 2010
Enrollment StartJun 1, 2010
Primary CompletionOct 1, 2015
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 16.1 years ago

Interventions

Simvastatindrug

Simvastatin 40mg qHS for 1 year

Placebodrug

Placebo 1 tablet qHS for 1 year